146 related articles for article (PubMed ID: 25348534)
1. In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolates.
Dubois J; Dubois M; Martel JF; Aubart K; Butler D
Antimicrob Agents Chemother; 2015 Jan; 59(1):707-10. PubMed ID: 25348534
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of macrolides against intracellular Legionella pneumophila.
Segreti J; Meyer P; Kapell K
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
O'Dwyer K; Hackel M; Hightower S; Hoban D; Bouchillon S; Qin D; Aubart K; Zalacain M; Butler D
Antimicrob Agents Chemother; 2013 May; 57(5):2333-42. PubMed ID: 23478958
[TBL] [Abstract][Full Text] [Related]
4. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Sato T; Tateda K; Kimura S; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1594-7. PubMed ID: 21220530
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1.
Mallegol J; Fernandes P; Melano RG; Guyard C
Antimicrob Agents Chemother; 2014; 58(2):909-15. PubMed ID: 24277019
[TBL] [Abstract][Full Text] [Related]
6. Review of azithromycin activity against Legionella spp.
Edelstein PH
Pathol Biol (Paris); 1995 Jun; 43(6):569-72. PubMed ID: 8539085
[TBL] [Abstract][Full Text] [Related]
7.
Dubois J; Dubois M; Martel JF
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094130
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic Resistance and Azithromycin Resistance Mechanism of Legionella pneumophila Serogroup 1 in China.
Jia X; Ren H; Nie X; Li Y; Li J; Qin T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405864
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan.
Miyashita N; Kobayashi I; Higa F; Aoki Y; Kikuchi T; Seki M; Tateda K; Maki N; Uchino K; Ogasawara K; Kurachi S; Ishikawa T; Ishimura Y; Kanesaka I; Kiyota H; Watanabe A
J Infect Chemother; 2018 May; 24(5):325-329. PubMed ID: 29459000
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
Kashimoto Y; Kurosaka Y; Karibe Y; Uoyama S; Fujikawa K; Namba K; Otani T; Yamaguchi K
Jpn J Antibiot; 2009 Oct; 62(5):452-9. PubMed ID: 20055122
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies for Legionella infection.
Pedro-Botet ML; Yu VL
Expert Opin Pharmacother; 2009 May; 10(7):1109-21. PubMed ID: 19405787
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
Edelstein PH; Edelstein MA; Lehr KH; Ren J
J Antimicrob Chemother; 1996 Jan; 37(1):117-26. PubMed ID: 8647752
[TBL] [Abstract][Full Text] [Related]
13. In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.
Edelstein PH; Hu B; Edelstein MA
Antimicrob Agents Chemother; 2005 Jun; 49(6):2533-5. PubMed ID: 15917565
[TBL] [Abstract][Full Text] [Related]
14. The activity of antibiotics against Legionella pneumophila: in vitro and in vivo studies.
Mizen L
J Antimicrob Chemother; 2001 Mar; 47(3):359-60. PubMed ID: 11222573
[No Abstract] [Full Text] [Related]
15. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs.
Edelstein PH; Shinzato T; Edelstein MA
J Antimicrob Chemother; 2001 Nov; 48(5):667-75. PubMed ID: 11679556
[TBL] [Abstract][Full Text] [Related]
16. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila.
Tan JS; File TM; DiPersio JR; DiPersio LP; Hamor R; Saravolatz LD; Stout JE
Clin Infect Dis; 2001 Jun; 32(11):1562-6. PubMed ID: 11340527
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Shinzato T; Doyle E; Edelstein MA
Antimicrob Agents Chemother; 2001 Aug; 45(8):2204-9. PubMed ID: 11451675
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic Resistance of
Pappa O; Chochlakis D; Sandalakis V; Dioli C; Psaroulaki A; Mavridou A
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32796666
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.
Edelstein PH; Edelstein MA
Antimicrob Agents Chemother; 1999 Jan; 43(1):90-5. PubMed ID: 9869571
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin.
Reda C; Quaresima T; Pastoris MC
J Antimicrob Chemother; 1994 Apr; 33(4):757-64. PubMed ID: 8056694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
